Kirsi Ketola
Kirsi Ketola
Unknown affiliation
Verified email at utu.fi
Title
Cited by
Cited by
Year
High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth
K Iljin, K Ketola, P Vainio, P Halonen, P Kohonen, V Fey, RC Grafström, ...
Clinical Cancer Research 15 (19), 6070-6078, 2009
1612009
Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress
K Ketola, M Hilvo, T Hyötyläinen, A Vuoristo, AL Ruskeepää, M Orešič, ...
British journal of cancer 106 (1), 99-106, 2012
1582012
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative …
RE Kast, JA Boockvar, A Brüning, F Cappello, WW Chang, B Cvek, ...
Oncotarget 4 (4), 502, 2013
1452013
The master neural transcription factor BRN2 is an androgen receptor–suppressed driver of neuroendocrine differentiation in prostate cancer
JL Bishop, D Thaper, S Vahid, A Davies, K Ketola, H Kuruma, R Jama, ...
Cancer discovery 7 (1), 54-71, 2017
1372017
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer
P Vainio, S Gupta, K Ketola, T Mirtti, JP Mpindi, P Kohonen, V Fey, ...
The American journal of pathology 178 (2), 525-536, 2011
1062011
High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion
L Lehtinen, K Ketola, R Mäkelä, JP Mpindi, M Viitala, O Kallioniemi, K Iljin
Oncotarget 4 (1), 48, 2013
922013
PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A–mediated inactivation in human malignant glioma
P Puustinen, MR Junttila, S Vanhatupa, AA Sablina, ME Hector, ...
Cancer research 69 (7), 2870-2877, 2009
882009
Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells
K Ketola, P Vainio, V Fey, O Kallioniemi, K Iljin
Molecular cancer therapeutics 9 (12), 3175-3185, 2010
762010
High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer
P Vainio, JP Mpindi, P Kohonen, V Fey, T Mirtti, KA Alanen, M Perälä, ...
PloS one 7 (6), e39801, 2012
612012
Regulation of tumor cell plasticity by the androgen receptor in prostate cancer
JL Bishop, A Davies, K Ketola, A Zoubeidi
Endocr Relat Cancer 22 (3), R165-R182, 2015
472015
The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 2017; 7: 54–71. doi …
JL Bishop, D Thaper, S Vahid, A Davies, K Ketola, H Kuruma, R Jama, ...
Mechanistic link between AR and the master regulator of neuronal …, 0
31
Using online game-based platforms to improve student performance and engagement in histology teaching
S Felszeghy, S Pasonen-Seppänen, A Koskela, P Nieminen, K Härkönen, ...
BMC medical education 19 (1), 1-11, 2019
302019
Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells
K Ketola, O Kallioniemi, K Iljin
PloS one 7 (12), e51470, 2012
252012
Targeting prostate cancer subtype 1 by forkhead box M1 pathway inhibition
K Ketola, RSN Munuganti, A Davies, KM Nip, JL Bishop, A Zoubeidi
Clinical Cancer Research 23 (22), 6923-6933, 2017
182017
Targeting Lyn regulates Snail family shuttling and inhibits metastasis
D Thaper, S Vahid, KM Nip, I Moskalev, X Shan, S Frees, ME Roberts, ...
Oncogene 36 (28), 3964-3975, 2017
182017
High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer
K Ketola, M Viitala, P Kohonen, V Fey, Z Culig, O Kallioniemi, K Iljin
Journal of molecular biochemistry 5 (1), 12, 2016
92016
Oxidative stress and diseases
V Lushchak, DV Gospodaryov
BoD–Books on Demand, 2012
72012
The β2-adrenergic receptor is a molecular switch for neuroendocrine transdifferentiation of prostate cancer cells
PR Braadland, H Ramberg, HH Grytli, A Urbanucci, HK Nielsen, ...
Molecular Cancer Research 17 (11), 2154-2168, 2019
62019
CD44s assembles hyaluronan coat on filopodia and extracellular vesicles and induces tumorigenicity of MKN74 gastric carcinoma cells
K Härkönen, S Oikari, H Kyykallio, J Capra, S Hakkola, K Ketola, ...
Cells 8 (3), 276, 2019
52019
Axon guidance-related factor FLRT3 regulates VEGF-signaling and endothelial cell function
S Jauhiainen, JP Laakkonen, K Ketola, PI Toivanen, T Nieminen, ...
Frontiers in physiology 10, 224, 2019
42019
The system can't perform the operation now. Try again later.
Articles 1–20